Pharma benefited from basing business overseas. An international tax effort could spur a rethink.
BioPharma Dive
NOVEMBER 28, 2023
U.S. tax law changes enacted six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.
Let's personalize your content